Atlas Trials

Combining Genomics and Imageomics to Predict the Sensitivity of Neoadjuvant Pemetrexed and Cisplatin Chemotherapy in Patients With Lung Adenocarcinoma

Clinical trial NCT05185544 · UNKNOWN

Trial details

NCT number
NCT05185544
Sponsor
Shanghai Zhongshan Hospital
Status
UNKNOWN
Study type
OBSERVATIONAL
Sensitivity
Start date
2022-01-01
Primary completion
2024-12-31
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.